[1] Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38 1:1-211; doi: 10.1177/0333102417738202.
[2] Del Valle López Martínez M, Pareja Román J, Jiménez Hernández MDU, Ceferino del Carmen Ramírez-Castillejo, María. Chronic Migraine with Medication Overuse: Clinical Pattern and Evolution from a Retrospective Cohort in Seville, Spain. SN Comprehensive Clinical Medicine. 2020; doi: 10.1007/s42399-020-00424-8.
[3] Goodhew SC. Migraine Literacy and Treatment in a University Sample. SN Comprehensive Clinical Medicine. 2019;1:749-57; doi: 10.1007/s42399-019-00124-y.
[4] Ali MW, Musami UB, Sa'ad FK, Omoaghe C, Danimoh MA, Ayoola YA, et al. Profile of Migraine Patients in a Developing Country: a Multicentre Study. SN Comprehensive Clinical Medicine. 2020; doi: 10.1007/s42399-020-00394-x.
[5] Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20 1:6; doi: 10.1186/s10194-018-0955-y.
[6] Tiseo C, Ornello R, Pistoia F, Sacco S. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain. 2019;20 1:49; doi: 10.1186/s10194-019-1000-5.
[7] Negro A, Martelletti P. Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Rev Neurother. 2019;19 8:769-76; doi: 10.1080/14737175.2019.1621749.
[8] De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother. 2020:1-15; doi: 10.1080/14737175.2020.1772758.
[9] Barbanti P, Aurilia C, Egeo G, Fofi L. Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci. 2019;40 Suppl 1:177-9; doi: 10.1007/s10072-019-03839-x.
[10] Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21 1:32; doi: 10.1186/s10194-020-01102-9.
[11] Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21 1:69; doi: 10.1186/s10194-020-01143-0.
[12] Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21 1:61; doi: 10.1186/s10194-020-01127-0.
[13] Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, et al. Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. Front Neurol. 2020;11:417; doi: 10.3389/fneur.2020.00417.
[14] American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59 1:1-18; doi: 10.1111/head.13456.
[15] Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377 22:2123-32; doi: 10.1056/NEJMoa1705848.
[16] Lipton R, Tepper s, Silberstein S, Kudrow D, Ashina M, Reuter U, et al. Conversion from Chronic Migraine (CM) to Episodic Migraine (EM) With Long-Term Erenumab Treatment (S17.008). Neurology. 2019;92.
[17] Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38 10:1611-21; doi: 10.1177/0333102418788347.
[18] Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, et al. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving >/=50%, >/=75%, and 100% response. Cephalalgia. 2020;40 1:28-38; doi: 10.1177/0333102419894559.
[19] Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, et al. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology. 2019;92 19:e2250-e60; doi: 10.1212/WNL.0000000000007452.
[20] Tepper SJ AM, Brandes J, Dolezil D, Silberstein SD, Winner PK, Zhang F, Cheng S, Mikol DD: Assessment of the long-term safety and efficacy of erenumab during open-label treatment of subjects with chronic migraine. In: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches. vol. 19. Florence, Italy: The Journal of Headache and Pain; 2018.
[21] Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16 6:425-34; doi: 10.1016/S1474-4422(17)30083-2.
[22] Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019;92 20:e2309-e20; doi: 10.1212/WNL.0000000000007497.
[23] Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18 1:101; doi: 10.1186/s10194-017-0787-1.
[24] Torres-Ferrus M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017;37 2:104-13; doi: 10.1177/0333102416636055.
[25] May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12 8:455-64; doi: 10.1038/nrneurol.2016.93.
[26] Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F, et al. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain. 2019;20 1:99; doi: 10.1186/s10194-019-1054-4.